



AMRI[®]

Allegra[®] Settlement Conference Call

**November 19, 2008
10:00 AM (EST)**

Forward-Looking Statements



This presentation may contain projections, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed in the Company's filings with the Securities and Exchange Commission. While this presentation represents management's current judgment on the future direction of the Company's business, such risks and uncertainties could cause actual results to differ materially from any future performance suggested herein. The Company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Allegra[®] Settlement – Why is it good for AMRI?



- Increases royalty revenue to AMRI from 2008 levels due to a diversification of streams of royalty payments
- Removes uncertainty related to a potential at-risk launch of a generic version of Allegra[®] D-12 by Teva Pharmaceuticals and Barr Laboratories
- The settlement agreements with Teva/Barr specifically affirm that the Allegra[®] patents are valid and enforceable and would be infringed without these agreements

Allegra® Settlement – Overview



- All litigation between AMRI and Teva/Barr will be dismissed
- AMRI License agreement with Sanofi-Aventis (SA) amended to allow sublicensing of Allegra® patents to Barr and Teva for US market only
 - Foreign markets not effected by this settlement
- Allegra® D-12 generic can launch no earlier than 11/1/2009
- Litigation with other defendants (Dr. Reddy's, Mylan and others) will continue
- Settlement is subject to review by FTC and certain states attorneys general

Allegra® Settlement – Financial Terms



➤ AMRI will receive:

- ✓ Upfront sublicense fee from SA of \$10 million
- ✓ Royalty payments on certain Allegra® - D product to be “held whole” for a finite period of time, then revert to contractual rate for the remaining term of patents
- ✓ Royalties on sales of fexofenadine by Barr and Teva, both for single entity product and D-12 product
- ✓ Increased royalty rate from SA on US sales of certain Allegra® -D product for the remaining term of the patents
- ✓ Royalties continue from SA for worldwide Allegra® sales and the US authorized generic sales through 2015

Allegra[®] Settlement – Financial Impact



- The guidance we previously provided on Allegra for 2008 is unchanged
- We estimate 2009 and 2010 royalty revenue to increase by 5% to 8% from 2008 levels*
- Sublicense fee to be amortized over remaining life of patents (through 2015)
- These estimates assume no unusual market erosion
- We will continue to pursue litigation against other defendants

* - Includes amortization of upfront payment



AMIRI[®]

